Arca
Skip to content
Tools
Tools

Mitochondrial complex I (NADH dehydrogenase)

Complex in Homo sapiens that 3 drugs act on.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 2
  • Genes: 50

Who is on it, and how far along

Every drug ChEMBL records acting on COXFA4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2
  • Other 1

Approved1

  • Metformin

Phase 30

    Phase 20

      Phase 12

      • ME-344
      • NV-128

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
      MetforminBoxed warningApprovedMerck KGaASmall moleculeInhibitor370
      ME-344Phase 1MEI PharmaSmall moleculeInhibitor0
      NV-128Phase 1—OtherInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Henagliflozin on Myocardial Fibrosis in Obese PatientsMetforminNot applicableNot yet recruitingJing MaNov 19, 2026
      Efficacy of Topical Metformin 30% Versus Minoxidil 5% in the Treatment of Alopecia Areata : Comparative StudyMetforminNot applicableRecruitingSohag UniversityNov 19, 2026
      An Evaluation of the Potential for VH4011499 Drug-drug-interactionsMetforminPhase 1Not yet recruitingViiV HealthcareNov 16, 2026
      Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 DiabetesMetforminPhase 4Not yet recruitingAllied Hospital FaisalabadNov 16, 2026
      Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 DiabetesMetforminPhase 3Not yet recruitingFayoum UniversityNov 12, 2026
      AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothMetforminPhase 3Not yet recruitingNovo Nordisk A/SNov 12, 2026
      A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothMetforminPhase 3Not yet recruitingNovo Nordisk A/SNov 12, 2026
      A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothMetforminPhase 3Not yet recruitingNovo Nordisk A/SNov 12, 2026

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363065, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.